SilcsBio, LLC Receives Phase II NIH SBIR Funding

 

FOR IMMEDIATE RELEASE: July 7, 2016

Ken Malone

SilcsBio, LLC

410.929.2305

Ken.Malone@silcsbio.com

 

SilcsBio, LLC Receives Phase II NIH SBIR Funding

 

Baltimore, Maryland: SilcsBio, LLC announced today a $1.3 million funding award from the National Institute of Health to develop new computer aided drug design (CADD) software. CADD software enables pharmaceutical companies to rapidly identify new drug opportunities and reduce the overall costs and time requirements to bring drugs to market.

“This funding will allow us to improve upon our already best in class accuracy and extend its use into protein-protein interactions.” states Dr. Alex MacKerell, Chief Science Officer of SilcsBio.

While CADD has been around for decades, SilcsBio uses a dramatically different approach that provides users with accurate drug design prediction and feedback capabilities that allow for rapid improvements in the way potential drugs interact with their protein and RNA targets.

“We’re pleased that NIH recognized how closely we’ve worked with our pharmaceutical company customers to propose novel software capabilities which will facilitate drug design leading to decreased development timelines and costs” says Kelli Booth, Chief Operating Officer at SilcsBio.

About SilcsBio: SilcsBio started operations in April 2013 based on licensed intellectual property developed by Dr. MacKerell at the University of Maryland, Baltimore where he is the Grollman-Glick Professor of Pharmaceutical Sciences and Director of the Computer-Aided Drug Design Center. The company is headquartered at Spark-Baltimore located at 8 Market Place, Suite 300, Baltimore, MD 21202.